Thank you to our Speakers, Sponsors, and Delegates who joined us in July for the Summit! If you are interested in the 2025 Summit, please register your interest below!
Implementing Sate-of-the-Art, Reproducible & Predictive Oncology Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
The Only Industry-Led Meeting Uniting Pharma and Biotech from the East Coast to Network and Discuss New Trends and Innovations in Tumor Models
In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.
The Annual Tumor Models Boston Summit is the only industry-led meeting uniting 200+ industry experts from pharma, biotech, academic KOLs and preclinical CROs to delve into the latest case studies in leveraging PDX models, genetically engineered mouse models, advanced 3D in vitro models and more. An opportunity to join industry leaders developing teams in preclinical, translational, pharmacology, discovery, pharmacodynamics, toxicity and biology to optimize and implement more translatable oncology models.
Your World Class 2024 Speaker Faculty Included:
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Hongyu-Xue-Bayer-150x150.jpg)
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Justine-RoderickRichardson-AstraZeneca-150x150.jpg)
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Deepali-Sawant-Amgen-150x150.jpg)
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Tamar-Uziel-AbbVie-150x150.jpg)
Tamar Uziel
Scientific Director, Research Fellow; Precision Medicine Oncology, Translational Research, Lead
Abbvie
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Francesca-Barone-Candel-Therapeutics-150x150.jpg)
![](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/Colles-Price-Takeda-150x150.jpg)
A Snapshot of What 2024 Had In-Store:
![1 1](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/1.png)
How to utilize PDX models to optimize patient representation with AstraZeneca
![2 2](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/2.png)
Developing and understanding the mode of action of tumor models using in vivo imaging biomarkers, with Merck
![3 3](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/3.png)
Identifying potential biomarkers before evaluating in the clinic, presented by Abbvie
![4 4](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/4-e1712247930332.png)
Use of in vivo and in vitro models to effectively recapitulate the tumor stroma and fibroblasts, with Amgen
![5 5](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/5.png)
Elucidating an in vivo gene therapy approach to reprogram the patients’ immune cells to fight cancer, with exclusive insights from Sanofi
![6 6](https://tumor-models.com/wp-content/uploads/sites/65/2024/04/6.png)
Uncovering the latest advances in utilizing humanized mouse models, GEMMs, CDX, PDX & organoids to optimize IO preclinical research & improve clinical translation